Research programme: antibody radiopharmaceuticals - Abzena/Telix Pharmaceuticals

Drug Profile

Research programme: antibody radiopharmaceuticals - Abzena/Telix Pharmaceuticals

Latest Information Update: 25 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abzena
  • Developer Abzena; Telix Pharmaceuticals
  • Class Antibodies; Antineoplastics; Immunoconjugates; Radiopharmaceutical diagnostics
  • Mechanism of Action Diagnostic imaging enhancers; Glutamate carboxypeptidase II modulators; Immunostimulants; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Prostate cancer

Most Recent Events

  • 18 Jul 2017 Abzena and Telix Pharmaceuticals agree to co-promote and co-develop radio-immunoconjugates worldwide for Prostate cancer
  • 18 Jul 2017 Early research in Prostate cancer (Diagnosis) in United Kingdom, Australia
  • 18 Jul 2017 Early research in Prostate cancer in United Kingdom, Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top